echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 【Immunity】A new combination of drugs combined with anti-PD-L1! Studies have found that this combination can overcome cancer immunotherapy resistance

    【Immunity】A new combination of drugs combined with anti-PD-L1! Studies have found that this combination can overcome cancer immunotherapy resistance

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    This article is the original of Translational Medicine Network, please indicate the source for reprinting

    Written by Sophia

    Immunotherapy is a way
    to treat cancer by reprogramming a patient's immune system to attack tumors.
    This advanced approach has greatly influenced the treatment of cancer patients, and there have been cases
    of long-term remission.
    Although immunotherapy is tumor-selective, it has shown extraordinary therapeutic effects

    In a new study published Jan.
    10 in Immunity led by Douglas Hanahan's group at the Swiss Institute of Experimental Cancer at the Swiss Institute of Experimental Cancer at the Ecole Polytechnique Fédérale de Lausanne, scientists discovered a way to
    break down the resistance of neuroendocrine pancreatic cancer mice.
    This cancer is very resistant to an immunotherapy called checkpoint blockade, in which patients receive a drug (checkpoint inhibitor) that blocks proteins that normally make the immune response too strong, and also prevents immune cells (T cells) from killing cancer cells


    Research background


    The development of cancer immunotherapy has revolutionized the way cancer patients are treated
    At present, at the forefront of immunotherapy development are immune checkpoint inhibitors, which have been clinically approved
    Despite abnormalities in remission, most cancer patients either do not respond to immune checkpoint blockade (ICB) or develop resistance to this treatment modality
    Therefore, immunomodulatory strategies are needed to disrupt this non-reactive mechanism of operation

    Research progress


    The scientists evaluated an engineered protein-antibody fusion called immune cytokines, which are increasingly used in immunotherapy
    They focused on the bispecific immune cytokine PD1-IL2v, which can localize tumors, activating killer T cells to attack cancer cells
    that drive tumor growth.

    Fluorescence microscopy of controlled tumors with PD1-IL2v for the treatment of tumors

    The researchers combined the immune cytokine PD1-IL2v with the immune checkpoint inhibitor anti-PD-L1 to enhance anti-tumor immunity against
    immunotherapy-resistant tumors.
    The authors said that PD1-IL2v is more effective
    when combined with immune checkpoint inhibitor anti-PD-L1.
    Compared to traditional anti-PD-1 therapies, PD1-IL2v induces stronger anti-tumor T cells by stimulating specific T cell subtypes, and anti-PD-L1 targets and disrupts the barrier established in the tumor microenvironment, namely pre-tumor macrophages and tumor vasculature, which synergistically fight anti-tumor immunity

    Combining these two molecules improves survival in tumor-bearing mice, producing a longer-lasting therapeutic effect
    than the bispecific immune cytokines themselves.
    The combination improves treatment outcomes by reprogramming immunosuppressive tumor-associated macrophages and tumor vasculature, making cancers more detectable
    by immune cells.

    Douglas Hanahan said: "This innovative immunotherapy combination sensitizes PD-1 stem-cell-like T cell-infiltrated immunotherapy-resistant tumors, and PD-1 stem-like T cells have recently been found to be important for maintaining an effective anti-tumor immune response, leading to tumor destruction and thus providing survival benefits
    " These results provide the rationale for clinical trials designed to evaluate PD1-IL2v and anti-PD-L1 combination therapies

    Research significance


    In conclusion, this study has demonstrated that the delivery of immunostimulatory cytokine IL2v to tumor antigen-expressing CD8 T cells through PD1-IL2v can effectively circumvent the inflammatory barrier and subordinate tumors insensitive to checkpoint inhibitors to immune attack, and this effect can be maintained
    by anti-PD-L1.
    Notably, the functional effect of anti-PD-L1 is not focused on blocking the PD1 checkpoint
    of CD8 T cells.
    In contrast, anti-PD-L1 has been shown to target PD-L1 expressed on tumor-infiltrating macrophages and tumor endothelial cells, reprogramming them into pro-inflammatory, antigen-presenting cells that help maintain and enhance dry-sample "resources" and effector CD8 T cell activity triggered by IL2v stimulation delivered by PD1-IL2v, resulting in a combination therapeutic effect




    Note: This article is intended to introduce the progress of medical research and cannot be used as a reference
    for treatment options.
    If you need health guidance, please go to a regular hospital

    Referrals, live broadcasts/events

    01/12 14:00-16:00 Online

    Olink Multiomics Cohort Forum

    Scan the code to participate for free

    03/02-03 09:00-18:00 Shanghai

    The 2nd Yangtze River Delta Single-cell Omics Technology Application Forum

    Scan the code to participate for free

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.